<DOC>
	<DOCNO>NCT00189813</DOCNO>
	<brief_summary>This study examine efficacy , safety tolerability different oral dose YM060 , 5-HT3 receptor antagonist , patient d-IBS .</brief_summary>
	<brief_title>A Study YM060 Diarrhea-predominant Irritable Bowel Syndrome ( d-IBS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patient meet Rome II criterion IBS subgroup diarrhea predominant IBS Patient severe cardiovascular disease , respiratory disease , renal disease , hepatic disease , digestive tract disease ( exclude IBS ) , blood disease , neurological psychiatric disease Patient report Type 1 Type 2 stool Bristol Stool Form Scale runin period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Nasea®</keyword>
	<keyword>Irribow®</keyword>
	<keyword>ramosetron</keyword>
</DOC>